Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin

Journal of Clinical Investigation

Volumn 100, Issue 1, 1997, Pages 58-67

  Waltz, David A ^b,c   Natkin, Lisa R ^a   Fujita, Ross M ^a   Wei, Ying ^a   Chapman, Harold A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cancer; Cell migration; Fibrinolysis; Metastasis; Monocyte

Indexed keywords

PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; VITRONECTIN;

ARTICLE; CANCER; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; FIBRINOLYSIS; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 0030757506     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119521     Document Type: Article

References (61)

1. Saksela, O., and D.B. Rifkin. 1988. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell Biol. 4:93-126.
2. Romer, J., T.H. Bugge, C. Pyke, L.R. Lund, M.J. Flick, J.L. Degen, and K. Dano. 1996. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med. 2:287-292.
3. Vassalli, J.-D., A.-P. Sappino, and D. Belin. 1991. The plasminogen activator/plasmin system. J. Clin. Invest. 88:1067-1072.
4. Blasi, F. 1993. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays. 15:105-111.
5. Vaheri, A., R.W. Stephens, E.-M. Salonen, J. Pollanen, and H. Tapiovaara. 1990. Plasminogen activation at the cell surface-matrix interface. Cell Differ. Dev. 32:255-262.
6. Plow, E.F., D.E. Freaney, J. Plescia, and L.A. Miles. 1986. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol. 103:2411-2420.
7. r 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100:86-92.
8. Ploug, M., E. Ronne, N. Behrendt, A.L. Jensen, F. Blasi, and K. Dano. 1991. Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem. 266:1926-1933.
9. Bertozzi, P., B. Astedt, L. Zenzius, K. Lynch, F. LeMaire, W. Zapol, and H.A. Chapman. 1990. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N. Engl. J. Med. 322:890-897.
10. Podor, T.J., P. Joshua, M. Butcher, D. Seiffert, D. Loskutoff, and J. Gauldie. 1992. Accumulation of type 1 plasminogen activator inhibitor and vitronectin at sites of cellular necrosis and inflammation. Ann. N.Y. Acad. Sci. 667: 173-177.
11. Fazioli, F., and F. Blasi. 1994. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol. Sci. 15:25-29.
12. Nusrat, A.R., and H.A. Chapman. 1991. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest. 87:1091-1097.
13. Waltz, D.A., L.Z. Sailor, and H.A. Chapman. 1993. Cytokines induce urokinase-dependent adhesion of human myeloid cells: a regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 91:1541-1552.
14. Estreicher, A., J. Muhlhauser, J.-L. Carpentier, L. Orci, and J.-D. Vassalli. 1990. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111:783-792.
15. Stahl, A., and B.M. Mueller. 1994. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 54:3066-3071.
16. Rosso, M.D., E. Anichini, N. Pedersen, F. Blasi, G. Gibbi, M. Pucci, and M. Ruggiero. 1993. Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem. Biophys. Res. Commun. 190:347-352.
17. Waltz, D.A., and H.A. Chapman. 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269:14746-14750.
18. Wei, Y., D.A. Waltz, N. Rao, R.J. Drummond, S. Rosenberg, and H.A. Chapman. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:32380-32388.
19. Wei, Y., M. Lukashev, D.I. Simon, S.C. Bodary, S. Rosenberg, M.V. Doyle, and H.A. Chapman. 1996. Regulation of integrin function by the urokinase receptor. Science (Wash. DC). 273:1551-1555.
20. Wang, N., E. Planus, M. Pouchelet, J.J. Fredberg, and G. Barlovatz-Meimon. 1995. Urokinase receptor mediates mechanical force transfer across the cell surface. Am. J. Physiol. 268:C1062-C1066.
21. Declerck, P.J., M. De Mol, M.-C. Alessi, S. Baudner, E.-P. Paques, K.T. Preissner, G. Muller-Berghaus, and D. Collen. 1988. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma: identification as a multimeric form of S protein (vitronectin). J. Biol. Chem. 263:15454-15461.
22. Seiffert, D., J. Mimuro, R.R. Schleef, and D.J. Loskutoff. 1990. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ. Dev. 32:287-292.
23. Singer, S.J., and A. Kupfer. 1986. The directed migration of eukaryotic cells. Annu. Rev. Cell Biol. 2:337-365.
24. Palecek, S.P., J.C. Loftus, M.H. Ginsberg, D.A. Lauffenburger, and A.F. Horwitz. 1996. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature (Lond.). 385:537-540.
25. Cai, T.-Q., and S.D. Wright. 1995. Energetics of leukocyte integrin activation. J. Biol. Chem. 270:14358-14365.
26. Simon, D.I., N.K. Rao, H. Xu, Y. Wei, O. Majdic, E. Ronne, L. Kobzik, and H.A. Chapman. 1996. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood. 88:3185-3194.
27. Niculescu, F., H.G. Rus, D. Porutiu, V. Ghiurca, and R. Vlaicu. 1989. Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. Atherosclerosis. 78:197-203.
28. Reilly, J.T., and J.R.G. Nash. 1988. Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. J. Clin. Pathol. 41:1269-1272.
29. Deng, G., S.A. Curriden, S. Wang, S. Rosenberg, and D.J. Loskutoff. 1996. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134:1563-1571.
30. Kanse, S.M., C. Kost, O.G. Wilhelm, P.A. Andreasen, and K.T. Preissner. 1996. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224:344-353.
31. Simon, D.I., H. Xu, and D.E. Vaughn. 1995. Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes. Biochim. Biophys. Acta. 1268:143-151.
32. Yatohgo, T., M. Izumi, H. Kashiwagi, and M. Hayashi. 1988. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct. Funct. 13:281-292.
33. Berkenpas, M.B., D.A. Lawrence, and D. Ginsburg. 1995. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 14: 2969-2977.
34. Sane, D.C., T.L. Moser, and C.S. Greenberg. 1991. Limited proteolysis of vitronectin by plasmin destroys heparin binding activity. Thromb. Haemostasis. 66:310-314.
35. Suzuki, S., M.D. Pierschbacher, E.G. Hayman, K. Nguyen, Y. Ohgren, and E. Ruoslahti. 1984. Domain structure of vitronectin: alignment of active sites. J. Biol. Chem. 259:15307-15314.
36. Chain, D., T. Kreizman, H. Shapira, and S. Shaltiel. 1991. Plasmin cleavage of vitronectin: identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett. 285:251-256.
37. Kost, C., W. Stuber, H.J. Ehrlich, H. Pannekoek, and K.T. Preissner. 1992. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J. Biol. Chem. 267:12098-12105.
38. Gechtman, Z., R. Sharma, T. Kreizman, M. Fridkin, and S. Shaltiel. 1993. Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin: use in mapping the PAI-1 binding site. FEBS Lett. 315: 293-297.
39. Kost, C., K. Benner, A. Stockmann, D. Linder, and K.T. Preissner. 1996. Limited plasmin proteolysis of vitronectin: characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor. Eur. J. Biochem. 236:682-688.
40. Andreasen, P.A., L. Sottrup-Jensen, L. Kjoller, A. Nykjaer, S.K. Moestrup, C.M. Petersen, and J. Gliemann. 1994. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett. 338:239-245.
41. Meissauer, A., M.D. Kramer, V. Schirrmacher, and G. Brunner. 1992. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp. Cell Res. 199:179-190.
42. Liu, G., M.A. Shuman, and R.L. Cohen. 1995. Co-expression of urokinase, urokinase receptor, and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer. 60:501-506.
43. Crowley, C.W., R.L. Cohen, B.K. Lucas, G. Liu, M.A. Shuman, and A.D. Levinson. 1993. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA. 90:5021-5025.
44. Kobayashi, H., J. Gotoh, M. Fujie, H. Shinohara, N. Moniwa, and T. Terao. 1994. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer. 57:727-733.
45. Min, H.Y., L.V. Doyle, C.R. Vitt, C.L. Zandonella, J.R. Stratton-Thomas, M.A. Shuman, and S. Rosenberg. 1996. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56: 2428-2433.
46. Seiffert, D., G. Ciambrone, N.V. Wagner, B.R. Binder, and D.J. Loskutoff. 1994. The somatomedin B domain of vitronectin: structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J. Biol. Chem. 269:2659-2666.
47. Eitzman, D.T., R.D. McCoy, X. Zheng, W.P. Fay, T. Shen, D. Ginsburg, and R.H. Simon. 1996. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97:232-237.
48. Mueller, B.M., Y.B. Yu, and W.E. Laug. 1995. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. Natl. Acad. Sci. USA. 92:205-209.
49. Soff, G.A., J. Sanderowitz, S. Gately, E. Verrusio, I. Weiss, S. Brem, and H.C. Kwaan. 1995. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 96:2593-2600.
50. Quax, P.H.A., G.N.P. van Muijen, E.J.D. Weening-Verhoeff, L.R. Lund, K. Dano, D.J. Ruiter, and J.H. Verheijen. 1991. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J. Cell Biol. 115:191-199.
51. Padro, T., J.J. Emeis, M. Steins, K.W. Schmid, and J. Kienast. 1995. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler. Thromb. Vasc. Biol. 15:893-902.
52. Gladson, C.L., and D.A. Cheresh. 1991. Glioblastoma expression of vitronectin and the αvβ3 integrin: adhesion mechanism for transformed glial cells. J. Clin. Invest. 88:1924-1932.
53. Landau, B.J., H.C. Kwaan, E.N. Verrusio, and S.S. Brem. 1994. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res. 54:1105-1108.
54. Sumiyoshi, K., K. Serizawa, T. Urano, Y. Takada, A. Takada, and S. Baba. 1992. Plasminogen activator system in human breast cancer. Int. J. Cancer. 50:345-348.
55. Jankun, J., H.W. Merrick, and P.J. Goldblatt. 1993. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J. Cell. Biochem. 53:135-144.
56. Sier, C.F.M., H.J.M. Vloedgraven, S. Ganesh, G. Griffioen, P.H.A. Quax, J.H. Verheijen, G. Dooijewaard, K. Welvaart, C.J.H. van de Velde, C.B.H.W. Lamers, and H.W. Verspaget. 1994. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology. 107:1449-1456.
57. Takeuchi, Y., A. Nakao, A. Harada, T. Nonami, T. Fukatsu, and H. Takagi. 1993. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am. J. Gastroenterol. 88:1928-1933.
58. 3 binding to vitronectin. Nature (Lond.). 383: 441-443.
59. Janicke, F., M. Schmitt, L. Pache, K. Ulm, N. Harbeck, H. Hofler, and H. Graeff. 1993. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat. 24:195-208.
60. Grondahl-Hansen, J., I.J. Christensen, C. Rosenquist, N. Brunner, H.T. Mouridsen, K. Dano, and M. Blichert-Toft. 1993. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:2513-2521.
61. Pedersen, H., J. Grondahl-Hansen, D. Francis, K. Osterlind, H.H. Hansen, K. Dano, and N. Brunner. 1994. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 54:120-123.